Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Exela Pharma Sciences, LLC.","sponsor":"Avadel Pharmaceuticals","pharmaFlowCategory":"D","amount":"$42.0 million","upfrontCash":"$14.5 million","newsHeadline":"Avadel Sells Sterile Injectables Portfolio; will Focus on Narcolepsy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Exela Pharma Sciences, LLC.

    Menu

    Exela Pharma Sciences, LLC.

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Exela Pharma Sciences, LLC.

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Avadel Sells Sterile Injectables Portfolio; will Focus on Narcolepsy

              Details:

              Company announced the sale of its portfolio of sterile injectable drugs used in the hospital setting, including three commercial products, Bloxiverz®, Vazculep®, and Akovaz®, as well as Nouress™ o Exela Sterile Medicines LLC.

              Lead Product(s): Neostigmine Methylsulfate

              Therapeutic Area: Musculoskeletal Product Name: Bloxiverz

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Avadel Pharmaceuticals

              Deal Size: $42.0 million Upfront Cash: $14.5 million

              Deal Type: Divestment July 01, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY